Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
While working as a health care administrator in Santa Cruz, California during the 2015 Zika virus outbreak, Jose Martinez realized his background in chemistry and pharmacology could be harnessed to set policies that are grounded in science.
Adults with Down syndrome (DS) are predisposed to Alzheimer’s disease (AD) and a characterization of glucose metabolism change throughout AD progression has yet to be performed in this population. Using FDG PET, regional glucose metabolism was evaluated across groups of cognitively stable DS (CS-DS), DS with mild cognitive impairment or Alzheimer’s disease (MCI-DS/AD), and healthy non-DS sibling controls.
